Edition:
India

Entera Bio Ltd (ENTX.OQ)

ENTX.OQ on NASDAQ Stock Exchange Capital Market

1.73USD
1:30am IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.73
Open
$1.75
Day's High
$1.76
Day's Low
$1.64
Volume
17,532
Avg. Vol
85,716
52-wk High
$3.35
52-wk Low
$1.60

Latest Key Developments (Source: Significant Developments)

Entera Bio Ltd Files For Mixed Shelf Of Upto $100 Million
Tuesday, 14 Jul 2020 

July 13 (Reuters) - Entera Bio Ltd ::ENTERA BIO LTD FILES FOR MIXED SHELF OF UPTO $100 MILLION - SEC FILING.  Full Article

Entera Bio Ltd Provides Update On Phase 2 Clinical Trial Of Eb613 In Postmenopausal Women With Osteoporosis
Tuesday, 7 Jul 2020 

July 7 (Reuters) - Entera Bio Ltd ::ENTERA BIO LTD PROVIDES UPDATE ON PHASE 2 CLINICAL TRIAL OF EB613 IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS.ENTERA BIO - INSTITUTIONAL REVIEW BOARDS APPROVE AMENDED PHASE 2 PROTOCOL WITH NEWLY ENROLLED PATIENTS RECEIVING 2.5 MG DOSE, 1.5 MG DOSE, OR PLACEBO.ENTERA BIO LTD - CONTINUES TO EXPECT COMPLETION OF ENROLLMENT IN TRIAL IN Q3:20.ENTERA BIO LTD - INTENDS TO FOLLOW ALL PATIENTS FOR BONE MINERAL DENSITY & BIOMARKER DATA AFTER 6 MONTHS OF TREATMENT.ENTERA BIO LTD - BIOMARKER DATA FROM HIGHER DOSE GROUPS EXPECTED IN EARLY Q1:21 WITH FULL SIX-MONTH BMD DATA EXPECTED IN EARLY Q2:21.  Full Article

Entera Bio Reports Revenues For 3 Months Ended Dec 31, 2018 $0.5 Mln
Thursday, 28 Mar 2019 

March 28 (Reuters) - Entera Bio Ltd ::ENTERA BIO REPORTS 2018 ANNUAL FINANCIAL RESULTS AND OPERATING UPDATE.ENTERA BIO - REVENUES FOR 3 MONTHS ENDED DEC 31, 2018 WERE $0.5 MILLION; DID NOT HAVE ANY REVENUES PRIOR TO SIGNING OF LICENSE AGREEMENT WITH AMGEN.ENTERA BIO LTD - COMPREHENSIVE LOSS FOR 3 MONTHS ENDED DEC 31, 2018, WAS $2.6 MILLION, COMPARED WITH $3.8 MILLION FOR 3 MONTHS ENDED DEC 31, 2017.  Full Article

Entera Bio Announce Transition In CFO Position
Thursday, 7 Mar 2019 

March 7 (Reuters) - Entera Bio Ltd ::ENTERA BIO ANNOUNCES A TRANSITION IN THE CHIEF FINANCIAL OFFICER POSITION.ENTERA BIO LTD - MIRA ROSENZWEIG, CHIEF FINANCIAL OFFICER, WILL BE LEAVING COMPANY IN MID-APRIL 2019.ENTERA BIO LTD - COMPANY HAS INITIATED A SEARCH PROCESS TO APPOINT A NEW CFO.ENTERA BIO - ROSENZWEIG HAS CONFIRMED TO CO THAT SHE HAS NO DISAGREEMENT WITH PRESENTATION OF COMPANY'S FINANCIAL STATEMENTS OR ACCOUNTING POLICIES.ENTERA BIO LTD - FOLLOWING DEPARTURE OF ROSENZWEIG IN MID-APRIL, CO WILL RETAIN AN OUTSOURCED CFO COMPANY UNTIL ONE IS FOUND.  Full Article

Entera Bio Ltd Reports Qtrly Loss Per Share Of $0.45
Tuesday, 22 Jan 2019 

Jan 22 (Reuters) - Entera Bio Ltd ::ENTERA BIO REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND OPERATING UPDATE.Q3 LOSS PER SHARE $0.45.QTRLY LOSS PER SHARE $0.45.CASH AND CASH EQUIVALENTS AT DEC 31, 2018 WERE ABOUT $11.5 MILLION.  Full Article

Entera Bio, Amgen Enter Collaboration In Inflammatory Disease, Other Illnesses
Tuesday, 11 Dec 2018 

Dec 11 (Reuters) - Entera Bio Ltd ::ENTERA BIO AND AMGEN ENTER STRATEGIC RESEARCH COLLABORATION IN INFLAMMATORY DISEASE AND OTHER SERIOUS ILLNESSES.ENTERA BIO - UNDER DEAL, CO TO BE ELIGIBLE TO RECEIVE UP TO $270 MILLION IN CLINICAL & COMMERCIAL MILESTONE PAYMENTS.ENTERA BIO - AMGEN WILL HAVE OPTION TO ADVANCE UP TO 3 LARGE MOLECULE PROGRAMS USING ENTERA’S ORAL DELIVERY TECHNOLOGY.ENTERA BIO - UNDER DEAL, CO TO RECEIVE INITIAL TECHNOLOGY ACCESS FEE FROM AMGEN & WILL BE RESPONSIBLE FOR PRECLINICAL DEVELOPMENT AT AMGEN’S EXPENSE.ENTERA BIO - UNDER DEAL, AMGEN IS RESPONSIBLE FOR CLINICAL DEVELOPMENT, MANUFACTURING & COMMERCIALIZATION OF ANY OF RESULTING PROGRAMS.ENTERA BIO - UNDER DEAL, CO WILL RETAIN ALL INTELLECTUAL PROPERTY RIGHTS TO ITS DRUG DELIVERY TECHNOLOGY.ENTERA BIO - AMGEN WILL RETAIN ALL RIGHTS TO ITS LARGE MOLECULES AND ANY SUBSEQUENT IMPROVEMENTS.  Full Article

Entera Bio Reports Q2 Loss Per Share $13.97
Tuesday, 21 Aug 2018 

Aug 20 (Reuters) - Entera Bio Ltd ::ENTERA BIO REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND OPERATING UPDATE.Q2 LOSS PER SHARE $13.97.FFECTIVE AS OF AUGUST 6, 2018, GERALD LIEBERMAN WAS APPOINTED TO ROLE OF CHAIRMAN OF BOARD OF DIRECTORS.AS OF JUNE 30, 2018, PRIOR TO COMPLETION OF IPO, COMPANY HAD CASH AND CASH EQUIVALENTS OF APPROXIMATELY $6.5 MILLION.IN Q4 OF 2018, COMPANY EXPECTS TO MEET WITH FDA TO DISCUSS DEVELOPMENT OF ORAL PTH/ EB613.  Full Article

BRIEF-Entera Bio Ltd Provides Update On Phase 2 Clinical Trial Of Eb613 In Postmenopausal Women With Osteoporosis

* ENTERA BIO LTD PROVIDES UPDATE ON PHASE 2 CLINICAL TRIAL OF EB613 IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS